These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 15922865)

  • 41. [Analysis of suppressive role of RASSF1A gene at 3p21.3 in lung cancer cell line A549].
    Zhang S; Shao K; Zhang CY; Zhou F; Wang W; Xiong MH; He J
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(13):908-11. PubMed ID: 16029530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer.
    Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT
    Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
    Wang J; Walsh G; Liu DD; Lee JJ; Mao L
    Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
    Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.
    Sekine I; Sato M; Sunaga N; Toyooka S; Peyton M; Parsons R; Wang W; Gazdar AF; Minna JD
    Oncogene; 2005 Apr; 24(16):2735-8. PubMed ID: 15735765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours.
    Pizzi S; Azzoni C; Bottarelli L; Campanini N; D'Adda T; Pasquali C; Rossi G; Rindi G; Bordi C
    J Pathol; 2005 Aug; 206(4):409-16. PubMed ID: 15887288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
    Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
    Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.
    Ito G; Uchiyama M; Kondo M; Mori S; Usami N; Maeda O; Kawabe T; Hasegawa Y; Shimokata K; Sekido Y
    Cancer Res; 2004 Jun; 64(11):3838-43. PubMed ID: 15172991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
    Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
    Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular genetics of small cell lung carcinoma.
    Wistuba II; Gazdar AF; Minna JD
    Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
    Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
    Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular pathogenesis of lung cancer and potential translational applications.
    Minna JD; Fong K; Zöchbauer-Müller S; Gazdar AF
    Cancer J; 2002; 8 Suppl 1():S41-6. PubMed ID: 12075701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
    Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
    Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
    Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
    Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.
    Hesson L; Dallol A; Minna JD; Maher ER; Latif F
    Oncogene; 2003 Feb; 22(6):947-54. PubMed ID: 12584574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Dammann R; Yang G; Pfeifer GP
    Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
    Sanchez-Cespedes M; Decker PA; Doffek KM; Esteller M; Westra WH; Alawi EA; Herman JG; Demeure MJ; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Mar; 61(5):2092-6. PubMed ID: 11280771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
    Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
    Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.